Kemble George 4
4 · Sagimet Biosciences Inc. · Filed Sep 8, 2023
Insider Transaction Report
Form 4
Kemble George
DirectorExecutive Chairman
Transactions
- Exercise/Conversion
Series A Common Stock
2023-09-07$0.79/sh+5,630$4,448→ 5,630 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-09-07−5,630→ 0 totalExercise: $0.79Exp: 2023-09-26→ Series A Common Stock (5,630 underlying)
Footnotes (1)
- [F1]This option is fully vested and exercisable as of the date hereof.